A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas.

Trial Profile

A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
    • 16 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 16 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top